DEALS: Affymetrix lands ParAllele acquisition


Affymetrix lands ParAllele acquisition


DEALS

WHO

WITH

WHAT

SCOOP

Affymetrix

ParAllele BioScience

$120M buyout

When used with Affymetrix GeneChip technology, ParAllele's proprietary assay effectively gives researchers a powerful "molecular microscope" for examining the entire genome.

NBTY

Solgar Vitamin and Herb

$115M buyout

Solgar manufactures and distributes nutritional supplements, including multivitamins, minerals, botanicals and specialty formulas.

Qiagen

artus Gesellschaft

$39.2M buyout

Artus is a leader in PCR-based molecular diagnostic tests for pathogenenic, genotyping and pharmacogenomic testing.

Chromos Molecular Systems

Targeted Molecules

Acquisition, stock and notes

Targeted Molecules has been focused on the research and development of two antibody product candidates for the treatment of multiple sclerosis and acute thrombosis.

Suggested Articles

What the NASH field needs, says Genfit CEO Pascal Prigent, is something like the Hb1Ac test for diabetes.

Blocking a newly discovered molecule produced by B cells could slow their flow into the brain and offer a new way to treat MS, a Canadian team found.

The action will see Kiadis switch its attention to earlier-stage natural killer cell therapies against solid tumors and hematological cancers.